BioCentury | Dec 3, 2020
Finance

Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click

AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million in a series A round led by Rock Springs Capital; T. Rowe Price Associates, Andreessen Horowitz, Menlo Ventures, Radical Ventures,...
BioCentury | Dec 1, 2020
Product Development

Nov. 30 Quick Takes: Grail piloting blood test in U.K.; plus Rhythm, Kadmon, venture rounds for Adrenomed, Xbiome, Transition

Grail piloting cancer blood test with NHS EnglandGrail Inc. announced a pilot program with NHS England using the company's Galleri blood test to monitor 140,000 asymptomatic participants aged 50 to 79 for three years, and...
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

Biogen tumbles after aducanumab panelAfter Friday’s FDA advisory committee meeting for Alzheimer’s therapy Aduhelm aducanumab, shares of Biogen Inc. (NASDAQ:BIIB) sank $92.64 (28%) to $236.26 Monday, obliterating nearly $14.3 billion of the company’s market value. Panelists not...
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

Ultragenyx, Scholar Rock offerings Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Scholar Rock Holding Corp. (NASDAQ:SRRK) raised follow-ons late Wednesday. Ultragenyx raised $400 million, while Scholar Rock raised $200 million via the shares and prefunded warrants after its stock more...
BioCentury | Oct 28, 2020
Deals

Thrive takeout could herald consolidation trend for early cancer detection companies

Thrive’s acquisition by Exact Sciences is the second in what could be a trend of big testing technology players investing in, and then buying up, early cancer detection companies. The news came along with upbeat...
BioCentury | Oct 27, 2020
Product Development

SMA data validate growth factor-targeting platform for Scholar Rock as stock price doubles

Scholar Rock’s interim Phase II data for SRK-015 in spinal muscular atrophy is breathing new life into the theory that blocking myostatin can improve muscle growth and function. It also provides validation...
BioCentury | Oct 23, 2020
Deals

Roche in $350M deal with Sommadossi’s Atea for what it believes could be first oral COVID-19 antiviral

Roche has partnered with Jean-Pierre Sommadossi’s Atea to gain rights to what it believes could be the first oral antiviral to treat COVID-19 patients outside the hospital setting. The therapy is also in testing in...
BioCentury | Oct 13, 2020
Finance

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

UAE fund, Novo invest €250M in EvotecEvotec SE (Xetra:EVT) raised €250 million ($295.5 million) via a private placement in which it sold shares to Mubadala Investment Co. and Novo Holdings A/S. Mubadala, a United Arab Emirates...
BioCentury | Oct 9, 2020
Finance

Everest balances local, international offerings in IPO that could be biggest yet on Hong Kong biotech chapter

Strong local demand allowed Everest to price what could become the largest IPO yet on the Hong Kong stock exchange’s biotech chapter with a share issue balanced between the offering’s local and international components. Cross-border...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...
Items per page:
1 - 10 of 986